ReviewFrontiers in oncology2025
Mechanisms and applications of N-Methyl-N'-nitro-N-nitrosoguanidine in animal tumor models: current situation and challenges.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide health and economic burden of cancer is substantial, necessitating urgent, focused prevention and treatment strategies. The investigation of cancer animal modeling techniques is particularly critical. N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), a nitrosamine carcinogen, is extensively utilized in the development of several tumor animal models due to its ability to replicate the natural onset of cancer. Nonetheless, MNNG exhibits a propensity for multi-organ carcinogenesis; yet, this aspect remains undiscussed. The MNNG model exhibits distinct characteristics depending on the route of administration, yet it also presents inherent limitations such as toxicity, environmental contamination, and inconsistent modeling outcomes. These issues necessitate standardized protocols to refine the model, ensuring it meets the criteria for efficient and precise tumor induction while adhering to animal welfare principles. This study examines the current applications of MNNG in gastric cancer models and models of other organs, its carcinogenic mechanisms, translational relevance to human tumors, and practical application features, with a particular focus on its use in gastric contexts. Furthermore, it summarizes and compares the advantages and disadvantages of various MNNG administration routes, as well as contrasts its carcinogenic properties with those of other chemical inducers.Through the examination of drug administration routes, dosage effects, combined modeling strategies, and model specificity, we endeavored to identify effective methods to enhance the specificity of target organs by optimizing the administration approach (local exposure, integration of advanced detection technologies with auxiliary factors). Furthermore, we encourage researchers to disclose negative results, as this practice helps improve model stability and accuracy, reduces research costs, and aligns with animal welfare guidelines.Experimental animals are crucial in scientific study. Future investigations must develop standardized protocols to minimize non-target organ damage and examine the interaction mechanisms between these animals and the tumor microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.